Phase 3 results posted, week of November 2, 2026: 4 industry trials
Industry sponsors posted results for 4 Phase 3 trials on ClinicalTrials.gov so far in the week of November 2 to 8, 2026. Together the trials enrolled 2,207 participants; the largest, Apnimed's AD109 trial, enrolled 660.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 8, 2026.
The trials
- Apnimed posts results of Phase 3 AD109 trial in obstructive sleep apnea. Sponsor: Apnimed. Condition: OSA. Intervention: AD109. Phase: Phase 3. Enrollment: 660 (actual). Results first posted November 3, 2026. Record: NCT05811247.
- Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes. Sponsor: Novo Nordisk A/S. Condition: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. Intervention: Semaglutide. Phase: Phase 3. Enrollment: 617 (actual). Results first posted November 2, 2026. Record: NCT04916470 (STEP HFpEF DM).
- Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL. Sponsor: Genmab. Condition: Diffuse Large B-cell Lymphoma. Interventions: Epcoritamab, Investigator's Choice Chemotherapy. Phase: Phase 3. Enrollment: 483 (actual). Results first posted November 3, 2026. Record: NCT04628494 (EPCORE DLBCL-1).
- Johnson & Johnson Consumer posts results of Phase 3 dental pain study. Sponsor: Johnson & Johnson Consumer Inc. (J&JCI). Condition: Pain. Interventions: Acetaminophen/Naproxen Sodium Fixed Combination, Naproxen Sodium, Acetaminophen. Phase: Phase 3. Enrollment: 447 (actual). Results first posted November 3, 2026. Record: NCT05761574.
By the numbers
- Trials: 4, from 4 lead sponsors.
- Participants: 2,207 in all across 4 trials; median 550 per trial.
- Largest: Apnimed's AD109 trial, 660. Smallest: Johnson & Johnson Consumer Inc. (J&JCI)'s NCT05761574 trial, 447.
- Phases as registered: 4 Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.